<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051685</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-15-CD-003</org_study_id>
    <nct_id>NCT03051685</nct_id>
  </id_info>
  <brief_title>Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crossover study to compare the BA of DFN-15 at 3 different doses versus the comparator to
      determine dose-proportionality of DFN-15 in healthy volunteers under fasting conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2015</start_date>
  <completion_date type="Actual">November 10, 2015</completion_date>
  <primary_completion_date type="Actual">August 14, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>DFN-15 maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>15 minutes</time_frame>
    <description>Area under the curve (AUC) 0-15 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>30 minutes</time_frame>
    <description>Area under the curve (AUC) 0-30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>1 hour</time_frame>
    <description>Area under the curve (AUC) 0-1 hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>2 hours</time_frame>
    <description>Area under the curve (AUC) 0-2 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-T</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-RefTmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-∞</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DFN-15 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 1</intervention_name>
    <arm_group_label>DFN-15 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 2</intervention_name>
    <arm_group_label>DFN-15 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 3</intervention_name>
    <arm_group_label>DFN-15 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects were male or female, at least 18 years of age but not older than 45 years of age.
        The main inclusion criteria were:

          1. non- or ex-smokers

          2. body mass index (BMI) ≥18.50 kg/m2 and &lt;30.00 kg/m2

          3. no clinically significant abnormality found in the 12-lead ECG performed at study
             entry

          4. negative pregnancy test for female subjects

          5. healthy according to medical history, complete physical examination (including vital
             signs) and laboratory tests (general biochemistry, hematology, urinalysis, and
             coagulation)

          6. Fecal occult blood determination negative at screening

        Exclusion Criteria:

          1. Females who were pregnant or were lactating

          2. Patients who had a history of allergic reactions to non-steroidal anti-inflammatory
             drugs (NSAIDs), including patients in whom aspirin or other NSAIDs induce the syndrome
             of asthma, rhinitis, nasal polyps or Samter's triad

          3. Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects

          4. History of significant gastrointestinal, liver or kidney disease that may affect drug
             bioavailability

          5. Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease

          6. Suicidal tendency, history of or disposition to seizures, state of confusion,
             clinically relevant psychiatric diseases, neurological impairment or cognitive
             dysfunction that, in the opinion of the investigator, would compromise validity of
             informed consent, study participation and compliance or data collection

          7. Presence of out-of-range cardiac intervals and/ or morphological changes suggestive of
             arrhythmias or ischaemic heart disease on the screening electrocardiogram (ECG) or
             other clinically significant ECG abnormalities

          8. History or current hypertension, bleeding disorders, ischaemic heart disease, stroke
             and/or cerebrovascular disease or renal disease

          9. History of asthma, urticaria, or allergic-type reactions after taking acetylsalicylic
             acid (ASA) or other NSAIDs

         10. Presence or history of gastric, duodenal or peptic ulcer or gastrointestinal bleeding

         11. Use of ASA or NSAIDs, or any product containing ASA or NSAIDs, in the previous 7 days
             before day 1 of this study

         12. Known presence of rare hereditary problems of galactose and /or lactose intolerance,
             Lapp lactase deficiency or glucose-galactose malabsorption

         13. Maintenance therapy with any drug or significant history of drug dependency (including
             marijuana and medical marijuana) or alcohol abuse (&gt; 3 units of alcohol per day,
             intake of excessive alcohol, acute or chronic) within 1 year

         14. Any clinically significant illness in the previous 28 days before day 1 of this study

         15. Any history of tuberculosis and/or prophylaxis for tuberculosis

         16. Positive urine screening of alcohol and/or drugs of abuse

         17. Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B)) or anti
             Hepatitis C Virus (HCV (C)) tests

         18. Females who were pregnant according to a positive pregnancy test

         19. Volunteers who took an investigational product (in another clinical trial) in the
             previous 28 days before day 1 of this study or who had already participated in this
             clinical study

         20. Volunteers who donated plasma in the previous 14 days before day 1 of this study

         21. Donation of 500 mL or more of blood (American Red Cross, clinical studies, etc.) in
             the previous 56 days before day 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pal A, Shenoy S, Gautam A, Munjal S, Niu J, Gopalakrishnan M, Gobburru J. Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clin Drug Investig. 2017 Oct;37(10):937-946. doi: 10.1007/s40261-017-0548-6.</citation>
    <PMID>28748412</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

